multiple myeloma
J&J, Legend get EU nod for myeloma CAR-T Carvykti
Phil Taylor
CAR-T therapies, Carvykti, EU, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval
0 Comment
BCMA Targeted Therapies Summit
Rhianna Price
adc, BCMA, CAR T, multiple myeloma, Oncology
0 Comment
Revolutionize your BCMA pipeline
CHMP backs J&J’s myeloma CAR-T therapy Carvykti
Phil Taylor
Abecma, BCMA Targeted Therapies, Bristol-Myers Squibb, CAR-T therapies, Carvykti, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology
0 Comment
Blackstone funds new trials of Sanofi’s Sarclisa in myeloma
Phil Taylor
Blackstone, Darzalex, Johnson & Johnson, multiple myeloma, Oncology, Sanofi, Sarclisa
0 Comment
Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod
Eloise McLennan
CAR-T therapies, Janssen, Legend Biotech, multiple myeloma, pharma
0 Comment
BMS cuts $3.15bn deal with Century for cancer cell therapies
Phil Taylor
acute myeloid leukaemia, Bristol-Myers Squibb, cell therapy, Century Therapeutics, Haematology, immuno-oncology, multiple myeloma, Oncology
0 Comment
J&J goes after another FDA approval for a cancer bispecific
Phil Taylor
BCMA Targeted Therapies, immuno-oncology, Janssen, Johnson & Johnson, multiple myeloma, Oncology, teclistamab
0 Comment
NICE rejects J&J’s Darzalex regimen for multiple myeloma
Phil Taylor
Darzalex, HEOR, Janssen, Johnson & Johnson, multiple myeloma, NHS, NICE
0 Comment